Skip to main content
Premium Trial:

Request an Annual Quote

Affy's eBioscience Divests Western Blot Product Line

NEW YORK (GenomeWeb News) – Affymetrix's eBioscience business has sold its TrueBlot IP/Western blot product line to Rockland Immunochemicals for an undisclosed price.

The TrueBlot reagents are used in cancer, cell signaling, infectious disease, and other life sciences research to generate data in immunoprecipitation and Western blot experiments. Western blotting is performed to determine expression and quantitate target proteins in biological samples.

"As eBioscience continues to focus its efforts on our evolving flow cytometry, immunoassay and immunohistochemistry applications in immunology, oncology and other therapeutic areas, we are pleased that the TrueBlot product line is a strong strategic fit for the Rockland portfolio," Don Tartre, GM of eBioscience, said in a statement.

Affy acquired eBioscience for $315 million earlier this year in an effort to diversify its product offerings.